Wandercraft acquired Ekso Bionics on 1 October 2026 from a subsidiary of ChronoScale Holdings (Nasdaq: CHRN). The deal was signed and closed on the same day, with financial terms undisclosed. Two of the best-known medical exoskeleton portfolios in the world now sit under one roof.
Key takeaways
- The transaction was signed and closed simultaneously, with unanimous board approval on both sides
- Financial terms were not disclosed
- Atalante X and EksoNR serve patients at more than 700 rehabilitation centres worldwide
- The portfolio carries FDA clearances and CE marking for stroke, spinal cord injury, MS and acquired brain injury
- Wandercraft also picks up Indego Personal, a modular wearable exoskeleton
Four exoskeletons, two markets
| Product | Origin | Use |
|---|---|---|
| Atalante X | Wandercraft | clinical rehabilitation, 150+ centres |
| EksoNR | Ekso Bionics | clinical rehabilitation |
| Eve | Wandercraft | personal home use, FDA cleared |
| Indego Personal | Ekso Bionics | personal use, modular design |
The split is clean: two devices for the clinic, two for the home. The acquisition is therefore not a technology swap but a merger of sales channels and clinical relationships on both sides of the Atlantic. Wandercraft grew up in France, Ekso in the United States.
Reimbursement matters more here than hardware
A personal exoskeleton without a reimbursement pathway stays a device for the few. Medicare covers qualifying personal exoskeletons under HCPCS code K1007 — and that mechanism decides whether Eve and Indego Personal reach homes. The combined portfolio now enters that channel with two products instead of one.
By bringing together our products, teams, and clinical relationships on both sides of the Atlantic, we have an exceptional opportunity to expand access to robotic mobility worldwide.
Matthieu Masselin, chief executive and co-founder of Wandercraft.
Exoskeletons are the opening, humanoids are the goal
Wandercraft is not stopping at medicine. In September the company said it had 12 customers for Calvin-40, an industrial humanoid built on the same self-balancing base as its exoskeletons. Renault Group plans to deploy 350 units within 18 months. Buying Ekso strengthens the medical leg that funds the other one.
Why it matters
The medical exoskeleton market is consolidating before it has matured. Instead of competing for the same few hundred rehabilitation centres, the two most recognisable players now share one clinical base and one reimbursement pathway. For patients that means a wider choice under a single brand. For the industry it signals that the edge in medical robotics is shifting from device design to access — to the clinic and to the payer.
What's next?
- The deal is already closed, so portfolio integration starts immediately — whether Atalante X and EksoNR survive as separate lines remains open
- Eve has held FDA clearance since August 2026 and Indego Personal has its own user base, so their overlap in the personal channel forces a product decision
- Renault Group is due to take 350 Calvin-40 units within 18 months of September 2026, which sets the real test for Wandercraft's second leg
Sources
- Wandercraft — Wandercraft Acquires Ekso Bionics
- Wandercraft — Wandercraft Secures 12 Calvin-40 Customers
- Humanoid Robotics Technology — Wandercraft Announces Acquisition of Ekso Bionics
